TRANQUILLO 2: Ritlecitinib Posts 21.86% F-VASI75 in Vitiligo
Ritlecitinib 100 mg drove a 21.86% F-VASI75 response at week 52 in the phase 3 TRANQUILLO 2 trial of nonsegmental vitiligo, against 2.40% on placebo. Pfizer plans FDA and EMA filings.
Topic
Phase 3 Trials
Topic
Phase 3 Trials
The Lancet publishes phase 3 data on rocatinlimab in atopic dermatitis
The Lancet publishes rocatinlimab phase 3 results from the global, placebo-controlled ROCKET-IGNITE and ROCKET-HORIZON trials in…